No CrossRef data available.
Article contents
Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada: commentary: author response
Published online by Cambridge University Press: 30 January 2025
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Commentary
- Information
- Copyright
- Copyright © The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists
References
Balbuena, L, Halayka, S, Lee, A, Ahmed, AG, Hinz, T, Kolla, N, et al. Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada. Br J Psychiatry [Epub ahead of print] 18 Sep 2024. Available from: https://doi.org/10.1192/bjp.2024.140.CrossRefGoogle ScholarPubMed
Lambert, PC. STPM3: Stata Module to Fit Flexible Parametric Survival Models. Statistical Software Components. 21 Feb 2024 edn. Boston College Department of Economics, 2023.Google Scholar
Forte, A, Pompili, M, Imbastaro, B, De Luca, GP, Mastrangelo, M, Montalbani, B, et al. Effects on suicidal risk: comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. J Psychopharmacol 2021; 35: 1074–80.CrossRefGoogle ScholarPubMed
Peters, E, Shamloo, A, Lodhi, RJ, Marcoux, G, Jackson, K, Halayka, S, et al. Medication gaps and antipsychotic polypharmacy in previously hospitalized schizophrenia patients: an electronic cohort study in three Canadian provinces. Front Psychiatry 2022; 13: 917361.CrossRefGoogle ScholarPubMed
eLetters
No eLetters have been published for this article.